Bausch + Lomb Co. (NYSE:BLCO) Given Average Rating of “Moderate Buy” by Brokerages

Bausch + Lomb Co. (NYSE:BLCO) has earned an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.00.

A number of equities analysts have issued reports on the company. Stifel Nicolaus increased their price target on Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft raised their price objective on Bausch + Lomb from $14.00 to $18.00 and gave the stock a “hold” rating in a research report on Thursday, August 1st. Evercore raised their price objective on shares of Bausch + Lomb from $15.50 to $17.00 and gave the company an “in-line” rating in a research report on Thursday, August 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $20.00 price target on shares of Bausch + Lomb in a research note on Thursday, August 1st. Finally, HC Wainwright boosted their target price on shares of Bausch + Lomb from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd.

Insider Buying and Selling at Bausch + Lomb

In other Bausch + Lomb news, CEO Brent L. Saunders purchased 32,250 shares of the stock in a transaction on Monday, August 5th. The shares were purchased at an average cost of $15.66 per share, for a total transaction of $505,035.00. Following the purchase, the chief executive officer now owns 595,169 shares of the company’s stock, valued at approximately $9,320,346.54. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.15% of the company’s stock.

Institutional Trading of Bausch + Lomb

Several institutional investors and hedge funds have recently bought and sold shares of BLCO. Blue Trust Inc. lifted its holdings in Bausch + Lomb by 14,052.2% during the 2nd quarter. Blue Trust Inc. now owns 3,255 shares of the company’s stock valued at $47,000 after purchasing an additional 3,232 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Bausch + Lomb during the second quarter worth approximately $173,000. Fore Capital LLC acquired a new stake in Bausch + Lomb during the 1st quarter worth approximately $384,000. Renaissance Capital LLC boosted its stake in Bausch + Lomb by 57.2% in the 2nd quarter. Renaissance Capital LLC now owns 36,286 shares of the company’s stock valued at $527,000 after purchasing an additional 13,210 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Bausch + Lomb in the second quarter valued at about $580,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Price Performance

BLCO opened at $20.68 on Tuesday. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.69. The company has a current ratio of 1.65, a quick ratio of 1.01 and a debt-to-equity ratio of 0.70. The firm has a market cap of $7.28 billion, a price-to-earnings ratio of -21.54, a PEG ratio of 1.76 and a beta of 0.48. The company has a fifty day simple moving average of $17.81 and a 200 day simple moving average of $16.15.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, July 31st. The company reported $0.13 EPS for the quarter, hitting the consensus estimate of $0.13. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a positive return on equity of 3.36% and a negative net margin of 10.15%. The business’s revenue was up 17.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.18 EPS. Equities research analysts expect that Bausch + Lomb will post 0.6 EPS for the current fiscal year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.